Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Oppenheimer

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022

Upgrades

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Amazon To $160? These Analysts Cut Price Targets On Amazon After Q3 Results

Amazon.com, Inc. (NASDAQ: AMZN) reported upbeat earnings for its third quarter, while sales missed estimates. The company also issued weak sales forecast for the fourth quarter.

Benzinga

Meta Platforms To $200? These Analysts Slash Price Targets On Meta Following Q3 Results

Meta Platforms, Inc. (NASDAQ: META) reported worse-than-expected Q3 EPS and issued Q4 revenue guidance with a midpoint below estimates. The company also guided FY23 expenses of $96 billion to $101 billion. Meta Platforms shares dropped 22.1% to $101.20 on Thursday.

Benzinga

Alphabet To $145? These Analysts Cut Price Targets On Alphabet After Downbeat Q3 Results

Alphabet Inc. (NASDAQ: GOOGL) reported weaker-than-expected earnings results for its third quarter after the closing bell on Tuesday.

Benzinga

This Chipotle Analyst Sees Further Upside In 2023 As The Cost Of Dining In Overtakes Dining Out

Chipotle is a very successful food chain business model, with contrasting market reach and strategy.

Zenger

Read news from The Economist, FT, and more,
with one subscription

This Chipotle Analyst Sees Further Upside In 2023 As The Cost Of Dining In Overtakes Dining Out

Food inflation is now up 11.2% for the 12 months ending in September, and the figure has a striking detail: food at home inflation is up 13%, while food away from home is only up 8.5% over the last 12 months.

Benzinga

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022

Benzinga

Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue forecast.

Benzinga

Oppenheimer Cuts AGCO's Price Target By ~8%

Oppenheimer analyst Kristen Owen lowered the price target on AGCO Corp (NYSE:AGCO) to $156 (an upside of 62%) from $169 while maintaining the Outperform rating on the shares. The analyst's reduced price target reflects a baseline valuation assumption of 2023 peak earnings, with space for multiple expansion should 2023 farm margin headwinds lessen, stated the…

Benzinga

IBD Stock Of The Day: 'Underappreciated' Construction Play Raises Roof On Gains

Carlisle Cos., which makes roofing products, is IBD Stock Of The Day. CSL stock is setting up in a base. Earnings growth is booming.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022

Benzinga

Oppenheimer Maintains Outperform Rating for IAC/InterActive: Here's What You Need To Know

Oppenheimer has decided to maintain its Outperform rating of IAC/InterActive (NASDAQ:IAC) and lower its price target from $155.00 to $135.00. Shares of IAC/InterActive are trading up 2.34% over the last 24 hours, at $80.94 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022

Upgrades

Benzinga

This Is What Whales Are Betting On Costco Wholesale

A whale with a lot of money to spend has taken a noticeably bullish stance on Costco Wholesale. Looking at options history for Costco Wholesale (NASDAQ:COST) we detected 28 strange trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Coinbase Needs To Regain This Level To Avoid Plunging To New Lows

Coinbase Global, Inc (NASDAQ: COIN) gapped up over 2% after rising over 4% intraday on Tuesday but immediately sold off, falling toward Tuesday’s low-of-day within the first 30 minutes of Wednesday's market open.

Benzinga

This Is What Whales Are Betting On Costco Wholesale

A whale with a lot of money to spend has taken a noticeably bearish stance on Costco Wholesale. Looking at options history for Costco Wholesale (NASDAQ:COST) we detected 30 strange trades.

Benzinga

Oppenheimer Initiates Timken At Outperform, Sees Sharp Upside

Timken Co (NYSE: TKR) coverage was initiated with an Outperform rating and a price target of $75 (an upside of 27%) by Oppenheimer analyst Bryan Blair. The analyst is confident in Timken's value-added portfolio transformation and realistic drivers for medium-term earnings outperformance. Blair states that the team's aggressive investments in renewable energy and automation strengthen its…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Upgrades

Benzinga

Oppenheimer Maintains Outperform Rating for Etsy, Lowers Price Target To $175

Oppenheimer has decided to maintain its Outperform rating of Etsy (NASDAQ:ETSY) and lower its price target from $215.00 to $175.00. Shares of Etsy are trading up 4.36% over the last 24 hours, at $117.87 per share. A move to $175.00 would account for a 48.47% increase from the current share…

Benzinga

Looking At Costco Wholesale's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Costco Wholesale (NASDAQ:COST). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Oppenheimer Maintains Outperform Rating for BioCryst Pharmaceuticals, Lowers Price Target To $16

Oppenheimer has decided to maintain its Outperform rating of BioCryst Pharmaceuticals (NASDAQ:BCRX) and lower its price target from $20.00 to $16.00. Shares of BioCryst Pharmaceuticals are trading down 1.62% over the last 24 hours, at $10.94 per share.

1 … 11 12 13 14

People

William Blair

32 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.